Parabilis to present zolucatetide data at ESMO 2026

Parabilis Medicines, Inc. (PBLS) reports that it plans to present updated clinical data from its ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Rhea-AI Filing Summary

Parabilis Medicines, Inc. (PBLS) reports that it plans to present updated clinical data from its ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The oral presentation is scheduled for Saturday, October 24 during a sarcoma-focused Proffered Paper session beginning at 2:45 p.m. CEST (8:45 a.m. ET). The company characterizes this disclosure as furnished under a Regulation FD-related item, not filed for liability purposes under the Exchange Act.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Figures

Presentation date: October 24, 2026 Session start time (CEST): 2:45 p.m. CEST Session start time (ET): 8:45 a.m. ET

3 metrics

Presentation date October 24, 2026 Date of the oral presentation at ESMO Congress 2026

Session start time (CEST) 2:45 p.m. CEST Start of sarcoma-focused Proffered Paper session

Session start time (ET) 8:45 a.m. ET Corresponding U.S. Eastern Time for the presentation

Key Terms

Phase 1/2 study, desmoid tumor, European Society for Medical Oncology (ESMO) Congress 2026, Proffered Paper session

4 terms

Phase 1/2 study medical

"updated clinical data from the ongoing Phase 1/2 study of zolucatetide"

A phase 1/2 study is an early-stage clinical trial that first tests a new drug or treatment for how safe it is and what dose people can tolerate (phase 1), then expands to see whether it shows initial signs of working in patients (phase 2). Think of it as a combined test-drive and small pilot launch: it helps companies gather crucial safety and early effectiveness data faster than separate trials, so investors use the results to gauge whether a treatment is worth further development or funding, while remembering that outcomes at this stage are still preliminary and risky.

desmoid tumor medical

"Phase 1/2 study of zolucatetide in desmoid tumor patients"

European Society for Medical Oncology (ESMO) Congress 2026 medical

"oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026"

Proffered Paper session medical

"during a sarcoma-focused Proffered Paper session beginning at 2:45pm CEST"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Parabilis Medicines (PBLS) announce in this 8-K?

Parabilis Medicines announced its intention to present updated clinical data from its ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients in an oral presentation at ESMO Congress 2026 in Madrid, Spain.

When will PBLS present the zolucatetide desmoid tumor data at ESMO 2026?

The updated Phase 1/2 zolucatetide desmoid tumor data will be presented on Saturday, October 24 during a sarcoma-focused Proffered Paper session beginning at 2:45 p.m. CEST (8:45 a.m. ET) at ESMO Congress 2026.

What type of study is PBLS conducting with zolucatetide?

Parabilis Medicines is conducting an ongoing Phase 1/2 study of zolucatetide in patients with desmoid tumors, and this study is the source of the updated clinical data to be presented at ESMO Congress 2026.

How is the information in this Parabilis Medicines 8-K treated under the Exchange Act?

The company states the information is being furnished under Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings except if specifically referenced.

Where will Parabilis Medicines present its zolucatetide data?

Parabilis Medicines will present the updated zolucatetide desmoid tumor data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, during a sarcoma-focused Proffered Paper session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:16 PM Accepted by SEC EDGAR 09/15/2026 - 04:15 PM Learn about SEC filing dates

0001657677false00016576772026-09-152026-09-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2026

Parabilis Medicines, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-43331	47-4505725
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
30 Acorn Park Drive
Cambridge, Massachusetts				02140
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 945-9510

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PBLS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01  Regulation FD Disclosure.  

Parabilis Medicines, Inc. is updating its guidance to reflect its intention to present updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The presentation is scheduled for Saturday, October 24 during a sarcoma-focused Proffered Paper session beginning at 2:45pm CEST (8:45am ET).

The information included under Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Parabilis Medicines, Inc.
Date:	September 15, 2026	By:	/s/ Thomas Kotarakos
			Thomas Kotarakos Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 27.4 KB